Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Locally Recurrent and Metastatic Breast Cancer
Interventions: DRUG: AMG 386 Placebo|DRUG: AMG 386|DRUG: Bevacizumab|DRUG: AMG 386|DRUG: AMG 386|DRUG: Paclitaxel
Sponsor: Amgen